Viagra, also known as sildenafil, along with its generic formulations, is among the most extensively studied pharmacological treatments for erectile dysfunction. Its mechanism of action is well established. Sildenafil inhibits the enzyme phosphodiesterase type five, thereby amplifying the vascular response to sexual stimulation and facilitating increased blood flow to penile tissue during erection (Goldstein et al., 1998; Burnett, 2006).
That same mechanism, however, explains why sildenafil carries clinically significant contraindications and risks. These risks are clearly documented in official prescribing information and international clinical guidelines (Katznelson et al., 1996; Andersson, 2011). In plain New York terms: it works well, but it is not candy, and it is not for everybody.
Understanding when Viagra can help and when its use may be dangerous is essential not only for patient safety, but also for preserving quality of life in men with erectile dysfunction (National Institutes of Health Consensus Panel, 1993).
1. Unstable Cardiovascular Disease
A man with pronounced cardiac symptoms, such as unstable angina, a recent myocardial infarction, or a recently sustained ischemic stroke, is considering taking Viagra.
Sildenafil causes systemic vasodilation. In patients with unstable cardiac function, this can significantly increase myocardial workload and precipitate serious adverse events (Kloner and Zusman, 1999). In these situations, Viagra is strictly contraindicated. Before even discussing its use, a comprehensive cardiovascular evaluation is mandatory (Jackson et al., 2010).
How Viagra may help: Once cardiovascular status is stable and formally assessed by a cardiologist, sildenafil may safely improve erectile function without increasing the risk of cardiac events (Kloner et al., 2003).
2. Concomitant Use of Nitrates
A man with coronary artery disease uses nitrates, such as nitroglycerin, to manage angina.
The simultaneous use of nitrates and phosphodiesterase type five inhibitors can cause a profound and potentially life-threatening drop in blood pressure (Katznelson et al., 1996; Zusman et al., 1999). This interaction is well known, well documented, and non-negotiable. Viagra and its generics are absolutely contraindicated in patients using nitrates in any form, including sublingual tablets and sprays (Food and Drug Administration, 2023).
What Viagra can do: If nitrates have been discontinued and a cardiologist confirms safety, sildenafil may restore erectile capacity during sexual stimulation (Jackson et al., 2010).
3. Hypersensitivity to Sildenafil or Excipients
A man develops urticaria, facial swelling, or breathing difficulty after prior sildenafil exposure.
Drug intolerance is an absolute contraindication. Any documented allergic reaction to sildenafil or its inactive components requires permanent discontinuation and immediate medical consultation (European Medicines Agency, 2022).
4. Severe Hypotension or Markedly Uncontrolled Hypertension
The patient presents with arterial blood pressure below ninety over fifty millimeters of mercury, or above one hundred seventy over one hundred millimeters of mercury.
Sildenafil can further reduce systemic blood pressure, particularly when combined with antihypertensive medications (Webb et al., 1999). This combination increases the risk of dizziness, syncope, and ischemic complications (Kloner and Zusman, 1999). In New York emergency rooms, this is not a rare story, unfortunately.
5. Advanced Liver or Kidney Disease
A man with severe hepatic or renal insufficiency plans to self-medicate with Viagra.
These conditions impair sildenafil metabolism and elimination. The result may be drug accumulation, amplified adverse effects, and toxicity (Muirhead et al., 2002). Dose adjustment or complete avoidance is required under specialist supervision (Food and Drug Administration, 2023).
6. Hereditary Retinal Disorders and Risk of NAION
A man with inherited retinal degeneration, such as retinitis pigmentosa, notices visual disturbances.
Rare but serious cases of non-arteritic anterior ischemic optic neuropathy have been reported after use of phosphodiesterase type five inhibitors (Pomeranz et al., 2002). Patients with preexisting optic nerve pathology should avoid Viagra, and sudden vision loss requires immediate medical attention (McGwin et al., 2006).
7. Hematologic Disorders
A man with sickle cell anemia, leukemia, or multiple myeloma considers taking Viagra.
These conditions predispose patients to priapism, a urological emergency that can result in tissue necrosis and permanent erectile damage (Burnett and Bivalacqua, 2007). In such cases, sildenafil is generally avoided unless strictly indicated and closely monitored (European Association of Urology Guidelines, 2023).
8. Anatomical Deformities of the Penis
A patient with Peyronie disease or significant penile curvature experiences pain during erection.
Structural abnormalities can transform an otherwise physiological erection into a painful event. In these cases, Viagra use must be carefully evaluated by a urologist (Mulhall et al., 2016).
How Viagra may help: In selected cases with mild deformity and specialist supervision, sildenafil may facilitate erection without worsening pain (Levine et al., 2015).
9. Interaction with Specific Medications
A man takes alpha blockers, pulmonary hypertension medications such as riociguat, or certain antiviral agents.
Sildenafil may potentiate hypotensive effects or cause clinically significant drug interactions. Dose adjustments or alternative therapies are often required (Kloner et al., 2004; Food and Drug Administration, 2023).
10. Recreational Use in Young Men Without Erectile Dysfunction
A man without diagnosed erectile dysfunction uses Viagra “for confidence” or “to boost performance.”
There is no medical indication for this practice. It may lead to adverse effects, sleep disturbances, altered receptor sensitivity, and psychological dependence (Harvard Medical School, 2019). Viagra is not intended to increase libido and is not designed for men without erectile dysfunction (National Institutes of Health Consensus Panel, 1993). In short: if nothing is broken, do not fix it with a prescription drug.
Conclusion
Viagra and its generics are effective and often safe treatments for erectile dysfunction. However, they are not universally appropriate (Goldstein et al., 1998).
Who Actually Needs Viagra or Its Generics
Sildenafil is indicated, following proper diagnostic evaluation, in men with:
- clinically confirmed erectile dysfunction;
- stable vascular disease after medical clearance;
- psychogenic or mixed erectile dysfunction associated with anxiety and stress responses;
- medication-induced erectile dysfunction after adjustment of primary therapy;
- chronic comorbid conditions following cardiology consultation (Kloner et al., 2003).
Based on contraindications, drug interactions, and comorbid conditions, thorough medical assessment is essential before prescription (Jackson et al., 2010; European Association of Urology Guidelines, 2023). Sildenafil does not eliminate the underlying cause of erectile dysfunction. It is one component of a comprehensive, physician-guided treatment strategy (Burnett, 2006).
Scientific References:
- Burnett, A. L. (2006). The role of nitric oxide in erectile dysfunction. Urology, 68(2), 3–8.
- Burnett, A. L., & Bivalacqua, T. J. (2007). Priapism: Current principles and practice. Urologic Clinics of North America, 34(4), 631–642.
- EAU Guidelines. (2023). Guidelines on sexual and reproductive health. European Association of Urology.
- EMA. (2022). Sildenafil product information. European Medicines Agency.
- FDA. (2023). Viagra (sildenafil citrate) prescribing information.
- Goldstein, I., et al. (1998). Oral sildenafil in the treatment of erectile dysfunction. New England Journal of Medicine, 338(20), 1397–1404.
- Jackson, G., et al. (2010). Sexual activity and cardiovascular disease. European Heart Journal, 31(11), 1373–1380.
- Katznelson, R., et al. (1996). Interaction of sildenafil with nitrates. American Journal of Cardiology, 77(7), 618–620.
- Kloner, R. A., & Zusman, R. M. (1999). Cardiovascular effects of sildenafil. American Journal of Cardiology, 83(5), 35C–44C.
- Mulhall, J. P., et al. (2016). Peyronie’s disease management. Journal of Sexual Medicine, 13(6), 905–923.
- NIH Consensus Panel. (1993). Impotence. JAMA, 270(1), 83–90.
- Pomeranz, H. D., et al. (2002). NAION associated with sildenafil. Journal of Neuro-Ophthalmology, 22(1), 9–13